查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1935147

嚴重急性呼吸綜合症 (SARS) 治療市場按藥物類別、適應症、給藥途徑、通路和地區分類

Severe Acute Respiratory Syndrome (SARS) Treatment Market, By Drug Class, By Indication, By Route of Administration, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2026 年嚴重急性呼吸道症候群 (SARS) 治療市場規模預計為 1,313 億美元，預計到 2033 年將達到 1,774 億美元，2026 年至 2033 年的年複合成長率（CAGR）為 4.4%。

報告內容 報告詳情
基準年： 2025 2026年市場規模： 1313億美元
歷史數據時期： 2020年至2024年 預測期： 2026年至2033年
預測期（2026-2033年）複合年成長率： 4.40% 2033 年的預測值： 1774億美元

嚴重急性呼吸綜合症（SARS）是一種由冠狀病毒引起的病毒性呼吸道疾病，最早在2000年代初被發現。儘管疫情已緩解，但由於其傳播迅速且臨床症狀嚴重，仍令人擔憂。 SARS治療市場的發展動力主要來自對抗病毒療法、支持性治療和預防策略的持續研究，旨在降低死亡率並促進患者康復。

目前的治療方法包括使用抗病毒藥物、皮質類固醇、蛋白酶抑制劑和核苷類似物，以及對重度呼吸窘迫患者進行氧氣療法和人工呼吸器等支持性治療。口服和靜脈注射等給藥方式的進步也對市場產生影響，有助於提高藥物的可及性和患者依從性。

製藥公司和研究機構持續投資研發新化合物和現有藥物的再利用，以應對未來的流行病。隨著人們對呼吸系統健康的日益關注以及對快速回應醫療解決方案的重視，SARS治療市場作為感染疾病控制的關鍵領域持續發展，強調醫療系統的創新性、安全性和韌性，以確保其能夠應對呼吸系統醫學領域的新挑戰。

市場動態

嚴重急性呼吸綜合症 (SARS) 治療市場的發展受到多種因素的影響，包括促進因素、限制因素、機會和挑戰。積極的一面是，對有效抗病毒療法和支持性護理方案的需求不斷成長，並持續推動創新，核苷類似物、蛋白酶抑制劑和皮質類固醇等藥物類別正在被探索。藥物遞送方式的進步，包括口服和靜脈注射製劑，進一步提高了患者的用藥便利性和依從性，從而增強了市場前景。

然而，目前仍存在一些限制因素，例如針對特異性疾病的治療方法供應有限、藥物研發高成本以及監管障礙導致新療法核准流程緩慢。儘管存在這些障礙，但仍存在巨大的機遇，尤其是在擴大針對冠狀病毒的生物製藥研究、開發聯合治療以及發展輔助治療技術（例如先進的呼吸支持系統）方面。

挑戰依然存在，包括由於感染模式難以預測而導致的需求波動，以及需要國際合作才能迅速應對並確保治療。總體而言，SARS治療市場體現了創新、風險和機會之間的微妙平衡，使其成為感染疾病控制和預防體系中的關鍵領域。

本次調查的主要特點

  • 本報告對嚴重急性呼吸症候群 (SARS) 治療市場進行了詳細分析，以 2025 年為基準年，給出了預測期 (2026-2033) 內的市場規模（十億美元）和復合年成長率 (%)。
  • 它還重點介紹了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
  • 該研究還提供了有關市場促進因素、限制因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
  • 本報告根據以下參數對嚴重急性呼吸綜合症 (SARS) 治療市場的主要企業進行了分析：公司概況、產品系列、主要亮點、財務績效和策略。
  • 本報告的研究結果將使負責人和企業經營團隊能夠就即將推出的產品、類型升級、市場擴張和行銷策略做出明智的決策。
  • 嚴重急性呼吸綜合症 (SARS) 治療市場報告涵蓋了該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
  • 相關人員將能夠透過用於分析嚴重急性呼吸綜合症 (SARS) 治療市場的各種策略矩陣輕鬆做出決策。

目錄

第1章 研究目標與前提條件

  • 調查目的
  • 先決條件
  • 簡稱

第2章 市場範圍

  • 報告概述
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map（COM）

第3章 市場動態、監理及趨勢分析

  • 市場動態
  • 促進要素
  • 抑制因素
  • 市場
  • 法規環境
  • 產業趨勢
  • 併購
  • 新系統實施和核准

4. 2026-2033年全球嚴重急性呼吸症候群（SARS）治療藥物市場（依藥物類別分類）

  • 抗生素
  • 抗病毒藥物
  • 皮質類固醇
  • 單株抗體
  • 其他

5. 2026-2033年全球嚴重急性呼吸症候群（SARS）治療市場（依適應症分類）

  • SARS-CoV
  • SARS-CoV2

6. 2026-2033年全球嚴重急性呼吸症候群（SARS）治療藥物市場（依給藥途徑分類）

  • 口服
  • 靜脈

7. 2026-2033年全球嚴重急性呼吸綜合症（SARS）治療市場按通路分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房

8. 2026-2033年全球嚴重急性呼吸綜合症（SARS）治療市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 俄羅斯
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • ASEAN
    • 澳洲
    • 韓國
    • 亞太其他地區
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 墨西哥
    • 其他拉丁美洲國家
  • 中東和非洲
    • 南非
    • 海灣合作理事會國家
    • 其他中東和非洲地區

第9章 競爭情勢

  • 公司簡介
    • Gilead Sciences Inc.
    • Hetero labs Ltd.
    • Cipla Ltd.
    • Cadila healthcare Ltd.
    • Ipca laboratories
    • GlaxoSmithKline plc.
    • Novartis
    • Pfizer Inc.
    • Roche Holding AG
    • AbbVie
    • Takeda Ltd.
    • Johnson &Johnson
    • Boehringer Ingelheim
    • Eli Lily &Co.
    • AstraZeneca plc.

第10章 分析師建議

  • 機會
  • 分析師觀點
  • Coherent Opportunity Map

第11章調查方法

  • 參考
  • 調查方法
簡介目錄
Product Code: CMI4494

Severe Acute Respiratory Syndrome (SARS) Treatment Market is estimated to be valued at USD 131.30 Bn in 2026 and is expected to reach USD 177.4 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.4% from 2026 to 2033.

Report Coverage Report Details
Base Year: 2025 Market Size in 2026: USD 131.30 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2026 To 2033
Forecast Period 2026 to 2033 CAGR: 4.40% 2033 Value Projection: USD 177.4 Bn

Severe Acute Respiratory Syndrome (SARS) is a viral respiratory illness caused by a coronavirus, first identified in the early 2000s. Although outbreaks have been contained, the disease remains a significant concern due to its potential for rapid transmission and severe clinical outcomes. The treatment market for SARS is shaped by ongoing research into antiviral therapies, supportive care, and preventive strategies that aim to reduce mortality and improve patient recovery.

Current therapeutic approaches include the use of antiviral agents, corticosteroids, protease inhibitors, and nucleoside analogues, alongside supportive interventions such as oxygen therapy and mechanical ventilation for patients with severe respiratory distress. The market is also influenced by advancements in drug delivery methods, including oral and intravenous formulations, which enhance accessibility and patient compliance.

Pharmaceutical companies and research institutions continue to invest in novel compounds and repurposed drugs to strengthen preparedness against potential future outbreaks. With growing awareness of respiratory health and a focus on rapid-response medical solutions, the SARS treatment market is evolving as a critical segment of infectious disease management. It emphasizes innovation, safety, and resilience in healthcare systems, ensuring readiness to address emerging challenges in respiratory medicine.

Market Dynamics

The dynamics of the Severe Acute Respiratory Syndrome (SARS) treatment market are shaped by a combination of drivers, restraints, opportunities, and challenges that influence its growth trajectory. On the positive side, increasing demand for effective antiviral therapies and supportive care solutions continues to drive innovation, with research focusing on drug classes such as nucleoside analogues, protease inhibitors, and corticosteroids. Advancements in drug delivery methods, including oral and intravenous formulations, further enhance patient accessibility and compliance, strengthening the market outlook.

However, the market faces restraints such as limited availability of disease-specific treatments, high costs associated with drug development, and regulatory hurdles that slow the approval process for novel therapeutics. Despite these barriers, opportunities remain significant, particularly in the expansion of biopharmaceutical research targeting coronaviruses, the development of combination therapies, and the growth of supportive care technologies like advanced respiratory support systems.

Challenges persist in the form of unpredictable outbreak patterns, which affect consistent demand, and the need for global collaboration to ensure rapid response and treatment availability. Overall, the SARS treatment market reflects a delicate balance of innovation, risk, and opportunity, positioning itself as a vital segment in infectious disease management and preparedness.

Key Features of the Study

  • This report provides in-depth analysis of the Severe Acute Respiratory Syndrome (SARS) treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the Severe Acute Respiratory Syndrome (SARS) treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Gilead Sciences Inc., Hetero labs Ltd., Cipla Ltd., Cadila healthcare Ltd., Ipca laboratories, GlaxoSmithKline plc., Novartis, Pfizer Inc., Roche Holding AG, AbbVie, Takeda Ltd., Johnson & Johnson, Boehringer Ingelheim, Eli Lily & Co., and AstraZeneca plc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The Severe Acute Respiratory Syndrome (SARS) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Severe Acute Respiratory Syndrome (SARS) treatment market.

Market Segmentation

  • By Drug Class
    • Antibiotics
    • Azithromycin
    • Antivirals
    • Ribavirin
    • Lopinavir
    • Ritonavir
    • Remdesivir
    • Corticosteroids
    • Methylprednisolone
    • Prednisolone
    • Dexamethasone
    • Monoclonal antibodies
    • Sotrovimab
    • Bamlanivimab and Etesevimab
    • REGEN-COV (Casirivimab and Imdevimab)
    • Baricitinib (Olumiant)
    • Others
  • By Indication
    • SARS-CoV
    • SARS-CoV2
  • By Route of Administration
    • Oral
    • Intravenous
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East & Africa
    • South Africa
    • GCC Countries
    • Israel
    • Rest of Middle East & Africa
  • Key players
    • Gilead Sciences Inc.
    • Hetero labs Ltd.
    • Cipla Ltd.
    • Cadila healthcare Ltd.
    • Ipca laboratories
    • GlaxoSmithKline plc.
    • Novartis
    • Pfizer Inc.
    • Roche Holding AG
    • AbbVie
    • Takeda Ltd.
    • Johnson & Johnson
    • Boehringer Ingelheim
    • Eli Lily & Co.
    • AstraZeneca plc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Indication
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Drivers
  • Restraints
  • Market
  • Regulatory Scenario
  • Industry Trend
  • Merger and Acquisitions
  • New System Launches/Approvals

4. Global Severe Acute Respiratory Syndrome (SARS) Treatment Market, By Drug Class, 2026-2033 (USD Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2026-2033
    • Segment Trends
  • Antibiotics
    • Introduction
    • Market Size and Forecast, 2026-2033, (USD Bn)
      • Azithromycin
  • Antivirals
    • Introduction
    • Market Size and Forecast, 2026-2033, (USD Bn)
      • Ribavirin
      • Lopinavir
      • Ritonavir
      • Remdesivir
  • Corticosteroids
    • Introduction
    • Market Size and Forecast, 2026-2033, (USD Bn)
      • Methylprednisolone
      • Prednisolone
      • Dexamethasone
  • Monoclonal antibodies
    • Introduction
    • Market Size and Forecast, 2026-2033, (USD Bn)
      • Sotrovimab
      • Bamlanivimab and Etesevimab
      • REGEN-COV (Casirivimab and Imdevimab)
      • Baricitinib (Olumiant)
  • Others
    • Introduction
    • Market Size and Forecast, 2026-2033, (USD Bn)

5. Global Severe Acute Respiratory Syndrome (SARS) Treatment Market, By Indication, 2026-2033 (USD Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2026-2033
    • Segment Trends
  • SARS-CoV
    • Introduction
    • Market Size and Forecast, 2026-2033, (USD Bn)
  • SARS-CoV2
    • Introduction
    • Market Size and Forecast, 2026-2033, (USD Bn)

6. Global Severe Acute Respiratory Syndrome (SARS) Treatment Market, By Route of Administration, 2026-2033 (USD Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2026-2033
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, 2026-2033, (USD Bn)
  • Intravenous
    • Introduction
    • Market Size and Forecast, 2026-2033, (USD Bn)

7. Global Severe Acute Respiratory Syndrome (SARS) Treatment Market, By Distribution Channel, 2026-2033 (USD Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2026-2033
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, 2026-2033, (USD Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, 2026-2033, (USD Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, 2026-2033, (USD Bn)

8. Global Severe Acute Respiratory Syndrome (SARS) Treatment Market, By Region, 2026-2033 (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2026 and 2033 (%)
  • North America
    • Regional Trends
    • Market Size and Forecast, By Drug Class, 2026-2033 (USD Bn)
    • Market Size and Forecast, By Indication, 2026-2033 (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2026-2033 (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Bn)
    • Market Share Analysis, By Country, 2026 and 2033 (%)
      • U.S.
      • Canada
  • Europe
    • Regional Trends
    • Market Size and Forecast, By Drug Class, 2026-2033 (USD Bn)
    • Market Size and Forecast, By Indication, 2026-2033 (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2026-2033 (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Bn)
    • Market Share Analysis, By Country, 2026 and 2033 (%)
      • U.K.
      • Germany
      • France
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Regional Trends
    • Market Size and Forecast, By Drug Class, 2026-2033 (USD Bn)
    • Market Size and Forecast, By Indication, 2026-2033 (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2026-2033 (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Bn)
    • Market Share Analysis, By Country, 2026 and 2033 (%)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Latin America
    • Regional Trends
    • Market Size and Forecast, By Drug Class, 2026-2033 (USD Bn)
    • Market Size and Forecast, By Indication, 2026-2033 (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2026-2033 (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Bn)
    • Market Share Analysis, By Country, 2026 and 2033 (%)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Middle East and Africa
    • Regional Trends
    • Market Size and Forecast, By Drug Class, 2026-2033 (USD Bn)
    • Market Size and Forecast, By Indication, 2026-2033 (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2026-2033 (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Bn)
    • Market Share Analysis, By Country, 2026 and 2033 (%)
      • South Africa
      • GCC Countries
      • Rest of the Middle East and Africa

9. Competitive Landscape

  • Company Profiles
    • Gilead Sciences Inc.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments/Updates
    • Hetero labs Ltd.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments/Updates
    • Cipla Ltd.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments/Updates
    • Cadila healthcare Ltd.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments/Updates
    • Ipca laboratories
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments/Updates
    • GlaxoSmithKline plc.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments/Updates
    • Novartis
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments/Updates
    • Pfizer Inc.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments/Updates
    • Roche Holding AG
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments/Updates
    • AbbVie
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments/Updates
    • Takeda Ltd.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments/Updates
    • Johnson & Johnson
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments/Updates
    • Boehringer Ingelheim
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments/Updates
    • Eli Lily & Co.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments/Updates
    • AstraZeneca plc.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments/Updates

10. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. Research Methodology

  • References
  • Research Methodology
  • About us and Sales Contact